1093066-74-0

Basic information

• Product Name: tert-Butyl 4-(3,3-difluoroazetidin-1-yl)piperidine-1-carboxylate
• Synonyms: tert-Butyl 4-(3,3-difluoroazetidin-1-yl)piperidine-1-carboxylate
• CAS NO: 1093066-74-0
• Molecular Formula: C13H22F2N2O2
• Molecular Weight: 276.3227864
• Mol File: 1093066-74-0.mol

Chemical Properties

• Boiling Point: 319.0±42.0 °C(Predicted)
• Appearance: /
• Density: 1.18±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 4.47±0.40(Predicted)
• CAS DataBase Reference: tert-Butyl 4-(3,3-difluoroazetidin-1-yl)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 4-(3,3-difluoroazetidin-1-yl)piperidine-1-carboxylate(1093066-74-0)
• EPA Substance Registry System: tert-Butyl 4-(3,3-difluoroazetidin-1-yl)piperidine-1-carboxylate(1093066-74-0)

Safety Data

• Hazardous Substances Data: 1093066-74-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Tert-Butyl 4-(3,3-difluoroazetidin-1-yl)piperidine-1-carboxylate is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of novel drugs. Its unique structure allows for the creation of compounds with specific therapeutic properties, enhancing the range of available treatments.
Used in Organic Chemistry Research:
In the field of organic chemistry, tert-Butyl 4-(3,3-difluoroazetidin-1-yl)piperidine-1-carboxylate is utilized as a research compound to explore the biological effects and potential applications of piperidine derivatives. Its presence in various chemical reactions can lead to new insights and discoveries in organic synthesis and medicinal chemistry.
Used in Biotechnology Industry:
Tert-Butyl 4-(3,3-difluoroazetidin-1-yl)piperidine-1-carboxylate is employed as a building block in the biotechnology sector, where it is used in the preparation of diverse chemical compounds. Its versatility in forming stable and functional molecules makes it an essential component in the development of new biotechnological products and processes.

Upstream product

• 288315-03-7 3,3-difluoroazetidine hydrochloride 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 1093066-73-9 4-(3,3-difluoroazetidin-1-yl)piperidine 

Relevant articles and documents

MUSCARINIC AGONISTS

This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1 or a salt thereof, wherein q, r, s, Q, R1, R2', R2 , R3 and R4 are as defined herein.

THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS

Thienopyrimidines of formula (I) wherein W and R1 to R4 are as defined in the claims, and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110δ isoform, which is a class Ia PI3 kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS

This invention provides a compound which is a purine of formula (Ia) or (Ib): and the pharmaceutically acceptable salts thereof that are inhibitors of PI3K and a selective for the p110δ isoform, which is a class Ia PI3 kinase, over other class Ia PI3 kinases and over class Ib kinases. The compounds may be used to treat diseases and disorders arisi from abnormal cell growth, function or behaviour associated with PI3 kinase such as cance immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

PHARMACEUTICAL COMPOUNDS

Furanopyrimidines of formula (I): wherein W represents a furan ring; R1 and R2 form, together with the N atom to which they are attached, a group of the following formula (IIa): in which A is selected from: (a) a 4- to 7-membered saturated N-containing heterocyclic ring which includes 0 or 1 additional heteroatoms selected from N, S and O, the ring being fused to a second ring selected from a 4- to 7-membered saturated N-containing heterocyclic ring as defined above, a 5- to 12-membered unsaturated heterocyclic ring, a 5- to 7-membered saturated O-containing heterocyclic ring, a 3- to 12- membered saturated carbocyclic ring and an unsaturated 5- to 12- membered carbocyclic ring to form a heteropolycyclic ring system, the heteropolycyclic ring system being unsubstituted or substituted; (b) a 4- to 7-membered saturated N-containing heterocyclic ring which includes 0 or 1 additional heteroatoms selected from N, S and O and which further comprises, linking two constituent atoms of the ring, a bridgehead group selected from -(CR'2)n- and -(CR'2)r-O-(CR'2)s- wherein each R' is independently H or C1 - C6 alkyl, n is 1, 2 or 3, r is 0 or 1 and s is 0 or 1, the remaining ring positions being unsubstituted or substituted; and (c) a group of formula (IIb): wherein ring B is a 4- to 7-membered saturated N-containing heterocyclic ring which includes 0 or 1 additional heteroatoms selected from N, S and O and ring B' is a 3- to 12- membered saturated carbocyclic ring, a 5- to 7- membered saturated O-containing heterocyclic ring or a 4- to 7-membered saturated N-containing heterocyclic ring as defined above, each of B and B' being unsubstituted or substituted; m is 0, 1 or 2; R3 is H or C1-C6 alkyl; R4 is an indole group which is unsubstituted or substituted; and Ra is selected from R, halo, CN, C(O)NR2, halo(C1-C6)alkyl, SO2R, SO2NR2, NRSO2R, NRC(O)R, NRC(O)OR and NRC(O)NR2 wherein each R is independently H or C1-C6 alkyl; and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110δ isoform, which is a class Ia PI3 kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.